Emerald Advisers Stake In Sarepta Therapeutics (SRPT) Was Has Increased; As Sangamo Biosciences (SGMO) Stock Value Rose, Ecor1 Capital Decreased Its Position

January 17, 2018 - By Nellie Frank

Ecor1 Capital Llc decreased its stake in Sangamo Biosciences Inc (SGMO) by 91.34% based on its latest 2017Q3 regulatory filing with the SEC. Ecor1 Capital Llc sold 2.35 million shares as the company’s stock rose 95.00% with the market. The institutional investor held 222,388 shares of the health care company at the end of 2017Q3, valued at $3.34 million, down from 2.57M at the end of the previous reported quarter. Ecor1 Capital Llc who had been investing in Sangamo Biosciences Inc for a number of months, seems to be less bullish one the $1.46B market cap company. The stock decreased 5.46% or $1 during the last trading session, reaching $17.3. About 2.56 million shares traded or 79.36% up from the average. Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has risen 29.78% since January 17, 2017 and is uptrending. It has outperformed by 13.08% the S&P500.

Emerald Advisers Inc increased its stake in Sarepta Therapeutics Inc (SRPT) by 2.06% based on its latest 2017Q3 regulatory filing with the SEC. Emerald Advisers Inc bought 18,077 shares as the company’s stock rose 22.49% with the market. The institutional investor held 893,484 shares of the health care company at the end of 2017Q3, valued at $40.53M, up from 875,407 at the end of the previous reported quarter. Emerald Advisers Inc who had been investing in Sarepta Therapeutics Inc for a number of months, seems to be bullish on the $3.89B market cap company. The stock decreased 2.23% or $1.37 during the last trading session, reaching $60.15. About 2.04M shares traded or 13.40% up from the average. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has risen 96.82% since January 17, 2017 and is uptrending. It has outperformed by 80.12% the S&P500.

Emerald Advisers Inc, which manages about $1.71 billion and $2.46 billion US Long portfolio, decreased its stake in Tile Shop Hldgs Inc (NASDAQ:TTS) by 220,640 shares to 838,699 shares, valued at $10.65M in 2017Q3, according to the filing. It also reduced its holding in Gsv Cap Corp (NASDAQ:GSVC) by 83,376 shares in the quarter, leaving it with 666,076 shares, and cut its stake in Nexstar Media Group Inc (NASDAQ:NXST).

Among 27 analysts covering Sarepta Therapeutics (NASDAQ:SRPT), 21 have Buy rating, 0 Sell and 6 Hold. Therefore 78% are positive. Sarepta Therapeutics had 95 analyst reports since August 5, 2015 according to SRatingsIntel. The firm has “Outperform” rating by Leerink Swann given on Thursday, March 2. RBC Capital Markets maintained it with “Outperform” rating and $98 target in Friday, December 16 report. The rating was initiated by Goldman Sachs on Tuesday, December 20 with “Neutral”. The stock has “Outperform” rating by RBC Capital Markets on Friday, October 28. The rating was maintained by Roth Capital on Thursday, August 20 with “Buy”. RBC Capital Markets maintained it with “Buy” rating and $6000 target in Wednesday, June 21 report. The firm has “Hold” rating by Jefferies given on Friday, October 23. Piper Jaffray downgraded Sarepta Therapeutics, Inc. (NASDAQ:SRPT) on Monday, January 18 to “Neutral” rating. The stock has “Outperform” rating by Cowen & Co on Tuesday, September 20. The company was upgraded on Monday, September 19 by Jefferies.

Investors sentiment increased to 2.88 in 2017 Q3. Its up 1.36, from 1.52 in 2017Q2. It is positive, as 24 investors sold SRPT shares while 27 reduced holdings. 63 funds opened positions while 84 raised stakes. 51.70 million shares or 25.22% more from 41.29 million shares in 2017Q2 were reported. Artal Gru Sa invested in 200,000 shares or 0.16% of the stock. First Mercantile Trust Comm holds 1,669 shares or 0.01% of its portfolio. American Int Gp invested 0.01% of its portfolio in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Hall Laurie J Trustee holds 0% or 130 shares. Ameriprise Finance Inc has 109,080 shares. Envestnet Asset Management stated it has 1,030 shares. Emerald Advisers Pa stated it has 893,484 shares or 1.65% of all its holdings. Pura Vida Ltd Liability Company reported 50,000 shares stake. Hanson Mcclain Inc, California-based fund reported 699 shares. Alliancebernstein Ltd Partnership stated it has 170,140 shares. Lord Abbett And Limited Liability Corp holds 0.08% or 586,405 shares. The Pennsylvania-based Lehman Fincl Resource has invested 0.15% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Emerald Mutual Fund Advisers owns 716,772 shares. Susquehanna Group Incorporated Limited Liability Partnership has invested 0.02% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). 72,543 are held by Rhumbline Advisers.

Since October 3, 2017, it had 0 insider purchases, and 1 insider sale for $575,000 activity.

Among 10 analysts covering Sangamo Biosciences (NASDAQ:SGMO), 7 have Buy rating, 1 Sell and 2 Hold. Therefore 70% are positive. Sangamo Biosciences had 22 analyst reports since August 8, 2015 according to SRatingsIntel. Wedbush maintained the shares of SGMO in report on Monday, August 14 with “Hold” rating. The stock of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) earned “Buy” rating by JP Morgan on Thursday, September 3. Jefferies reinitiated Sangamo Therapeutics, Inc. (NASDAQ:SGMO) on Thursday, June 22 with “Buy” rating. The firm has “Sell” rating given on Tuesday, September 8 by Zacks. The stock of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) earned “Neutral” rating by Janney Capital on Thursday, August 4. The firm has “Overweight” rating given on Wednesday, November 15 by PiperJaffray. The firm has “Neutral” rating given on Tuesday, November 1 by Wedbush. Piper Jaffray maintained the stock with “Buy” rating in Wednesday, January 3 report. The stock has “Neutral” rating by Piper Jaffray on Wednesday, October 19. The rating was maintained by Jefferies on Friday, October 13 with “Buy”.

Ecor1 Capital Llc, which manages about $750.32M US Long portfolio, upped its stake in Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) by 190,000 shares to 957,992 shares, valued at $5.51M in 2017Q3, according to the filing. It also increased its holding in Regulus Therapeutics Inc (NASDAQ:RGLS) by 1.53 million shares in the quarter, for a total of 5.24 million shares, and has risen its stake in Kura Oncology Inc Com.

Analysts await Sangamo Therapeutics, Inc. (NASDAQ:SGMO) to report earnings on February, 27. They expect $-0.18 earnings per share, down 28.57% or $0.04 from last year’s $-0.14 per share. After $-0.15 actual earnings per share reported by Sangamo Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 20.00% negative EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: